NCT07217613 Prospective Evaluation of Silk Fibroin Incision Dressings in ACL Reconstruction
| NCT ID | NCT07217613 |
| Status | Recruiting |
| Phase | — |
| Sponsor | NYU Langone Health |
| Condition | Anterior Cruciate Ligament Reconstruction |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-10-14 |
| Primary Completion | 2026-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2025-10-14 with a primary completion date of 2026-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to compare the incidence of early postoperative skin complications including allergic contact dermatitis, blistering, and erythema between silk fibroin incision dressings and cyanoacrylate closure in patients undergoing anterior cruciate ligament reconstruction.
Eligibility Criteria
Inclusion Criteria: * Age 14 to 60 years * Scheduled for primary or revision ACL reconstruction (ACLR) * Able and willing to provide informed consent (≥18 years) or assent with parental/guardian permission (ages 14-17) * Able and willing to comply with all study-related procedures and follow-up visits Exclusion Criteria: * Active dermatologic conditions at or near the surgical site (e.g., eczema, psoriasis, dermatitis, open wounds) * Immunocompromised state (e.g., uncontrolled HIV, ongoing chemotherapy, chronic corticosteroid therapy) * Known or suspected allergy or hypersensitivity to silk fibroin or cyanoacrylate adhesives * Uncontrolled diabetes (defined as most recent HbA1c ≥ 8.0, if available; not measured for study purposes) * Active systemic infection at the time of enrollment
Contact & Investigator
Eric J. Strauss, MD
PRINCIPAL INVESTIGATOR
NYU Langone Health
Frequently Asked Questions
Who can join the NCT07217613 clinical trial?
This trial is open to participants of all sexes, aged 14 Years or older, up to 60 Years, studying Anterior Cruciate Ligament Reconstruction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07217613 currently recruiting?
Yes, NCT07217613 is actively recruiting participants. Contact the research team at layne.estes@nyulangone.org for enrollment information.
Where is the NCT07217613 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT07217613 clinical trial?
NCT07217613 is sponsored by NYU Langone Health. The principal investigator is Eric J. Strauss, MD at NYU Langone Health. The trial plans to enroll 100 participants.